Are atrial fibrillation guidelines altering management? A community based study

被引:6
作者
Murdoch, DL [1 ]
O'Neill, K
Jackson, J
McMahon, A
Rumley, A
Wallace, I
Lowe, GDO
Tait, RC
机构
[1] So Gen Hosp, Dept Cardiol, Glasgow G51 4TF, Lanark, Scotland
[2] Royal Infirm, Dept Haematol, Glasgow G31 2ER, Lanark, Scotland
[3] Royal Infirm, Dept Vasc Med, Glasgow G31 2ER, Lanark, Scotland
[4] Univ Glasgow, Glasgow Primary Care NHS Trust, Glasgow, Lanark, Scotland
[5] Univ Glasgow, Robertson Ctr Biostat, Glasgow, Lanark, Scotland
关键词
D O I
10.1177/003693300505000409
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Aims: We wanted to determine the prevalence of atrial fibrillation (AF) in a community based cross sectional study in greater Glasgow and how current anti-thrombotic management compares to published guidelines. Methods: 1466 patients with AF were identified in General Practices in our community and 1008 consented to take part. Their demographic details and medical history were recorded. Results: 1466 patients (mean age 73.4; 55% female) with AF were identified, in our community, giving a prevalence of 1%. 53 % of patients were on warfarin therapy. Of those not receiving warfarin, only one third had a putative contra-indication. The proportion of AF patients on warfarin increased with increasing stroke risk, and over the period of the study. Conclusions: Prevalence of AF was in keeping with previous estimates. The proportion of patients with AF receiving warfarin therapy appears to be increasing. In the moderate risk group, there was a tendency to use more warfarin in the younger age groups compared to the elderly. It was in the moderate and low risk groups that there was still evidence of deviation from published guidelines.
引用
收藏
页码:166 / 169
页数:4
相关论文
共 22 条
[1]  
Albers GW, 2003, LANCET, V362, P1691
[2]  
ASINGER RW, 1989, ARCH NEUROL-CHICAGO, V46, P727
[3]  
Connolly SJ, 1999, CAN MED ASSOC J, V161, P533
[4]   Oral anticoagulation and hemorrhagic complications in an elderly population with atrial fibrillation [J].
Copland, M ;
Walker, ID ;
Tait, RC .
ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (17) :2125-2128
[5]   Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study [J].
Devereaux, PJ ;
Anderson, DR ;
Gardner, MJ ;
Putnam, W ;
Flowerdew, GJ ;
Brownell, BF ;
Nagpal, S ;
Cox, JL .
BMJ-BRITISH MEDICAL JOURNAL, 2001, 323 (7323) :1218-1221
[6]   Are the results of randomized controlled trials on anticoagulation in patients with atrial fibrillation generalizable to clinical practice? [J].
Evans, A ;
Kalra, L .
ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (11) :1443-1447
[7]   Management of atrial fibrillation:: discrepancy between guideline recommendations and actual practice exposes patients to risk for complications [J].
Frykman, V ;
Beerman, B ;
Rydén, L ;
Rosenqvist, M .
EUROPEAN HEART JOURNAL, 2001, 22 (20) :1954-1959
[8]   Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation [J].
Hylek, EM ;
Go, AS ;
Chang, YC ;
Jensvold, NG ;
Henault, LE ;
Selby, JV ;
Singer, DE .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (11) :1019-1026
[9]   Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness [J].
Kalra, L ;
Yu, G ;
Perez, I ;
Lakhani, A ;
Donaldson, N .
BMJ-BRITISH MEDICAL JOURNAL, 2000, 320 (7244) :1236-1239
[10]  
LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449